Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS
Status:
Terminated
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
The goals of this study are to learn about the effectiveness, the side-effects, if waiting to
give the idarubicin and cytarabine may change the side effects or effectiveness, and to
identify factors to predict for responses to this therapy. The trial will examine combination
of three chemotherapy drugs. These drugs are decitabine, idarubicin, and cytarabine.